# Standards for Specialized Nutrition Support (Parenteral Nutrition)

彰化基督教醫院營養部 林佳青

# Introduction

- In critically ill patients, malnutrition is associated with impaired immune function, impaired ventilatory drive, and weakened respiratory muscles, leading to prolonged ventilatory dependence and increased infectious morbidity and mortality.
- Malnutrition is prevalent in intensive care unit (ICU) patients, has been reported as being as high as 40%, and is associated with increased morbidity and mortality.

JPEN 27:355-373, 2003

# Introduction

The benefits of nutrition support in the critically ill include improved wound healing, a decreased catabolic response to injury, improved gastrointestinal (GI) structure and function, and improved clinical outcomes, including a reduction in complication rates and length of stay, with accompanying cost savings. *However, nutrition support is not without adverse effects or risks.* 

The use of nutrition support in ICUs has been shown to vary from 14% to 67% of all patients in the ICU. Recent surveys report the use of PN ranging from 12% to 71% and the use of EN ranging between 33% and 92% of patients receiving nutrition support in the ICU.
JPEN 27:355-373, 2003

# **Nutrition Support Service**


Function to assess and manage patients determined to be nutritionally at risk.

- Improved patient outcomes.
- Decreased length of hospitalization
- Improved cost effectiveness

# **Specialized Nutrition Support Administration**

# Enteral nutrition or Parenteral nutrition

- Khursheed N Jeejeebhoy. <u>Total parenteral</u> <u>nutrition: potion or poison?</u> American Journal of Clinical Nutrition74(2): 160-163,2001
- Woodcock NP, Enteral v.s. parenteral nutrition: a pragmatic study. Nutrition 17(1): 1-12,2001



Perspect Crit Care 1989; 2:1.(14)

Theory of the benefits of enteral nutrition

Prevents mucosal atrophy ?

Table TPN and intestinal atrophy in humans

Human studies have not shown any intestinal atrophy with complete bowel rest and TPN, even 1 mo after the withdrawal of food by mouth.

enteral nutrition for  $\geq 10 \text{ d}$ 

Groos et al, 1996

Atrophy after 7-12 wk of TPN

Theory of the benefits of enteral nutrition

# Prevents bacterial translocation ?

Bacterial translocation was identified by culturing the same organism in the blood as in the intestine and the mesenteric lymph nodes.

There is little evidence in humans that TPN causes atrophy of the intestinal mucosa and that EN prevents bacterial translocation.

TPN OF EN

Moore et al, 1992

only 2 of 132 p'ts had translocation


#### Enteral Versus Parenteral Nutrition: A Pragmatic Study

Nicholas P. Woodcock, FRCS, Dietmar Zeigler, FRCS, M. Diane Palmer, BSc, RGN, Paul Buckley, FRCA, Charles J. Mitchell, FRCP, and John MacFie, MD, FRCS

From the Combined Gastroenterology Unit, Scarborough Hospital, Scarborough, UK

Controversy persists as to the optimal means of providing adjuvant nutritional support. The aim of this study was to compare enteral nutrition (EN) and parenteral nutrition (TPN) in terms of adequacy of nutritional intake, septic and nonseptic morbidity, and mortality. This was a prospective pragmatic study, whereby the route of delivery of nutritional support was determined by the attending clinician's assessment of gastrointestinal function. Patients considered to have inadequate gastrointestinal function were given TPN (group 1), while those deemed to have a functioning gastrointestinal tract received EN (group 2). Patients in whom there was reasonable doubt as to the adequacy of intestinal function were randomized to receive either TPN (group 3) or EN (group 4). The trial setting was a large district general hospital with a dedicated nutrition team. A total of 562 patients were included in the study (331 males; median age 67 y). Gastrointestinal function on entry into the study was considered inadequate in 267 patients who were given TPN (group 1) and adequate in 231 whom received EN (group 2). There was clinical uncertainty about the adequacy of gut function in 64 patients (11.4%) who were randomized to receive either TPN (group 3, 32 patients) or EN (group 4, 32 patients). The incidence of inadequate nutritional intake was significantly higher in group 4 compared with group 3 (78.1% versus 25%, P < 0.001). Complications related to the delivery system and other feed-related morbidity were significantly more frequent in both EN groups compared with the respective TPN groups. EN was associated with a higher overall mortality in both nonrandomized and randomized patients. There were no significant differences observed in the incidences of septic morbidity between patients receiving TPN and those given EN. EN is associated with a higher incidence of inadequate nutritional intake, complications related to the delivery system, and other feed-related morbidity than TPN. There is no evidence from this study to support a difference between the two modalities in terms of septic morbidity. Patients in whom there is reasonable doubt as to the adequacy of gastrointestinal function should be fed by the parenteral route. Nutrition 2001;17:1-12. @Elsevier Science Inc. 2001

Key words: enteral nutrition, parenteral nutrition, morbidity, nutritional support, gut function






FIG. 3. Adequacy of nutritional intake. (A) Duration of feeding by designated route; (B) percentage of patients receiving less than 80% of target intake.

#### TABLE IV.

#### INCIDENCE OF SEPTIC MORBIDITY

	Nonrandomized patients			
	Group 1 (TPN)	Group 2 (EN)	P value	
Incidence of septic complications	84/267 (31.5%)	81/231	0.48, NS	
Mean no. of complications per patient (± SEM)	(31.5%) $0.44 \pm 0.05$	(35.1%) $0.45 \pm 0.05$	>0.05, NS	
Mean no. of complications per infected patient (± SEM)	$1.40 \pm 0.07$	$1.30 \pm 0.07$	>0.05, NS	

	Randomized patients			
	Group 3 (rTPN)	Group 4 (rEN)	P value	
Incidence of septic complications	16/32 (50%)	10/32 (31.3%)	0.13, NS	
Mean no. of complications per patient (± SEM)	$0.75 \pm 0.16$	$0.41 \pm 0.12$	>0.05, NS	
Mean no. of complications per infected patient (± SEM)	$1.50 \pm 0.16$	$1.30 \pm 0.15$	>0.05, NS	

EN, enteral nutrition; rEN, randomized EN; TPN, parenteral nutrition; rTPN, randomized TPN.

#### TABLE V.

	Nonrandomized patients		
	Group 1 (TPN)	Group 2 (EN)	<i>P</i> value
Well nourished or mild/	31/108	54/134	0.06, NS
moderately malnourished (NRI $\geq$ 83.5)	(28.7%)	(40.2%)	
Severely malnourished	41/124	20/64	>0.5, NS
(NRI <83.5)	(33.1%)	(31.3%)	
	R	andomized pati	ents
	Group 3 (rTPN)	Group 4 (rEN)	P value
Well nourished or mild/	6/16	4/14	>0.5, NS
moderately malnourished (NRI $\geq$ 83.5)	(37.5%)	(28.6%)	
Severely malnourished	10/15	5/15	0.07, NS
Outerer indicionationed			

#### SEPTIC MORBIDITY IN RELATION TO NUTRITIONAL STATUS

EN, enteral nutrition, NRI, nutritional risk index; rEN, randomized EN; TPN, parenteral nutrition; rTPN, randomized TPN.




FIG. 4. Septic morbidity in relation to duration of feeding.




FIG. 6. Other complications.




FIG. 7. Overall mortality rates.

# Conclusion

TPN undertaken by experienced teams does not cause more complications than does EN.
 When indicated because of the inability to give EN, TPN is beneficial in the treatment of malnutrition but is not a cure for all illnesses.

# Specialized Nutrition Support Administration




FIG. 2. Route of Administration of Specialized Nutrition Support<sup>2</sup> (Taken from the A.S.P.E.N. Clinical Pathways and Algorithms for Delivery of Parenteral and Enteral Nutrition Support in Adults).

Relative Contraindications to Early Enteral Feeding

Small bowel ileus
Bowel obstruction
Intra-abdominal sepsis
Necrotizing pancreatitis
High-output gastrointestinal fistulas
Short-bowel syndrome

	- · · ·		- · · ·			Evidence from RCTs#				
Type of nutritional support <sup>®</sup>	Nutritional status of partient <sup>®</sup>	Expected resumption of oral/enteral nutrition <sup>®</sup>	Clinical condition	Basefit	Effect not likely	Effect may/ may not be present	Harm	No ACTs	Recommendation®	
PN	Not severe mainstrition	=14 days	Perioperative:						-	
			Phoop UGI cancer Other	Prop	UGI+can	cer→B			694 (1)	
Not sev	ere malnutrition		Orealogie:	1						
	ed resumption of en	nteral	Charro/radiation therapy BMT			+	+		E CIII	
	nutrition $\leq 14$ days	literar	Liver disease:							
	2		Alcoholic hepatitis Other		+			+	CIII.	
			Pancreatitis:							
			Ramson < 2 Ramson = 2				+		E	
			IBD:						-	
			UC Crohn's disease		+				0	
			Podiatrice:		+				ш	
			LBW intents with IEE		+		_		0	
			Other	LBW	infants v	without IE	F→A	+++++++++++++++++++++++++++++++++++++++	AF C	
			AIDS		+				D.	
			Chronic pulnonary disease Renal failure:		+				ū	
			Acute					+	C=	
			Chronic Critically ill:					+	Ċ=	
			Burn injury				+.0		E.	
			Trauma		+				0	
NT	1		Respirator-bound Other		+			+	0 C=	
	re malnutrition l resumption of en	toral	Other conditions	~ ~				+	C=	
nutrition	> 14 days	wiai	Short/inadequate bowel:	Short	bowel>	3 mo life	expecta	ancy→	A 🛌	
nutrition	> I lady5		-C3 months life expectancy					+	E.	
Severe n	nalnutrition		Other Processative	nreon	erative→	B		+	C= B	
	d resumption of en	teral	Other	preop		Ď		+	Ċ=	
nutrition	: not applicable		Periopentive Masteria benetitie		+				0	
			Alcoholic hepatitis Hepatic encephalopathy	+=	+				6	
			LBW infants with IEF		+				0	
			Pancreatitis—Rereson < 2 Other		+			+	0 C=	

#### Table 16. Recommendations for the Use of Parenteral Nutrition or Protein-Sparing Therapy in Various Clinical Conditions


Gastroenterology 2001;121:970-1001.

# Reducing Mortality and Morbidity Rates with Parenteral Nutrition

- PN can improve the clinical outcome in some conditions in which malnutrition and inflammatory stress coexist, especially p't with anorexia, malabsorption, or bowel dysfunction.
  - Major trauma

- Acute hepatic encephalopathy
- Major burns ARF
- Head injury BMT
- Sepsis syndrome AIDS
- Major general surgical procedures in moderately to severely malnourished p't
- Major abdominal or thoracic surgery in moderately to severely malnourished p't
- Major abdominal or thoracic surgery for cancer in moderately to severely malnourished p't

NST工作流程及 各專業人員職責、分工內容介紹 --以彰基為例--





高振渾[TPN11]	TPN11 TPN會診輸入功能_正式	本院-STEVENKA0[192.168.199.20
病歷號:10771898 姓名:		選取患者(Q) 離開(E)
住院帳號:700212193 床號: K SIC 03	入院日期:93/1/19 上午 11:07:21	
主治醫師:62980 鄭清源	診 斷:1 578.91 上胃腸道出血	編輯狀態:新建

確認



#### 急項檢驗:(照會前需開立) 全選 全不選

檢驗名稱		開立日期	收費碼	檢序	
<b>⊡</b> Glucose: AC	mg/dL	·	FBIGAC	6	
🗹 Total Protein	群項		FBIAG	6	
🗹 Prealbumin	mg/dL		FBIPAB	6	
🗹 Transferrin	mg/dL		FBITRA	6	
🗹 Bilirubin D	mg/dL		FBIBID	6	
🗹 Bilirubin T	mg/dL		FBIBIT	6	
GOT(AST)	U/L		FBIGOT	6	
GPT(ALT)	U/L		FBIGPT	6	
Alk-P-tase	U/L		FBIALK	6	•

🏄 開始 🛛 📀 🙆 👋 🛛 🙆 收... 🖓 Tp... 🦓 Ult... 💏 C+... 🛃 2 O 🗸 🔬 彰... 🔤 文... 🚺 tpn... 🛛 🛗 🦿 < 🤽 🐠 下午 05:38

財團法人彰化基督教醫院 臨床營養醫療支援小組	病歷號碼: 16006581 性別: 女
會診單(成人)	姓名:
CONSULTATION SHEET (ADULT)	床 號: K-650 年齡: 64

病情摘要:

Request臨床營養醫療支援小組Consultation

Diagnosis:2 518.81 呼吸衰竭 3 686 皮膚及皮下組織之其他局部感染 6 401.9 自發性高血壓,未明示為惡性或良性 8 599.0 泌尿道感染,未明示位置者 10 996.62 其他血管裝置物、種植及移植物所致之感染及發炎反應11 569 83 腸穿孔

13 558.9 其他及未明示之非傳染性胃腸炎及大腸炎14 709.2 疤痕病態及皮膚纖維化 Clinical Summary:

The 64 y/o female patient is a case of enterocutaneous fistula, ischemia bowel post op, DM with medical control. This time she admitted to our ward due to wound poorly care due to a lot of discharge from endtrocutaneous fistula, and we need your excellent experience for further nutrition suport due to NPO, thanks a lot!!

Nutrition Assessment Required Data:

Height	(Cm)			Dept.	201 一般外科	Referred by Dr. 楊力衡
Actual wt.	(Kg) 1BW	(Kg) or AdjBW	0(Kg)	Date:	2004/2/13 E4	- 09:43:55

# **Role of Nutrition Support Team Members**

# 🕹 Nurse

- 1. Be a resource person for <u>patients</u>, <u>staff</u> and <u>local health</u> <u>care providers</u> regarding parenteral nutrition therapy and central venous catheters.
- Monitor quality care for parenteral nutrition therapy and central venous catheters.
- 3. Participate in the discharge planning and patient education of home parenteral nutrition therapy patients.
- Follow-up with home parenteral nutrition therapy patients after discharge from the hospital.

# **Role of Nutrition Support Team Members**

# 😻 Dietitian

- 1. Assess the nutritional status of the patient and determine nutritional needs.
- Develop and implement a plan of nutritional care based on assessment of needs.
- 3. Monitor and evaluate nutritional status on an ongoing basis and recommend changes as needed.
- Educate patients, physicians, and other health professionals on types and methods of nutritional support for hospital and home use.

### **Management of Total Parenteral Nutrition**

### Indication for TPN

- Nonfunctional gastrointestinal tract
  - Small-bowel syndrome
  - Inflammatory bowel disease
  - Enterocutaneous fistula
  - Chronic intestinal Pseudo-Obstruction
  - Severe diarrhea
  - Severe malnutrition or severe catabolism
  - Severe GI toxicities associated with chemotherapy and radiation

### **Management of Total Parenteral Nutrition**

### Indication for TPN

- Organ failure
  - Pancreatitis
  - Hepatic failure
  - Renal failure
  - Multiple organ failure
- Perioperation patient
- Anorexia nervosa
- Neonatal conditions
- Hyperemesis gravidarum

### **Role of Nutrition Support Team Members**

# 🕹 Physician

- Indicate whether the patient needs to have parenteral nutrition therapy.
- Assess the patient and order appropriate nutrition and electrolytes needed for the patient after evaluating lab values.
- 3. Evaluate the patient for potential line infections.



### **Nutritional Assessment**

Registered dietitians will provide a nutritional assessment upon request. An assessment may include the following parameters:

- Diet history includes information about weight change, food intake (if applicable), and nutritional support history.
- Calculation of calories, protein, fat, and carbohydrate from all sources of nutrition support are made.

### **Nutritional Assessment**

Registered dietitians will provide a nutritional assessment upon request. An assessment may include the following parameters:

- 3. Nutritional needs
  - a. Basal energy needs are calculated from patient's weight, height, and age. Additional energy needs are based on an assessment of activity and metabolic needs.
  - b. Protein needs are determined by the patient weight and metabolic state (e.g., burn, sepsis, renal disease)
  - c. Fluid requirements are 30 35 cc/kg (average sized adults), or 25 cc/kg (65 years of age or older)

高振渾[TPN12]	TPN12 TPN營養評估功能_正式	本院-STEVENKA0[192.168.199.205]
病 歴 號: <sup>3845243</sup> 姓名: 住院帳號: <sup>700218002</sup> 床號: K 651 主治醫師: <sup>21591</sup> 張宏基	性別:     年齡:     71     成人       ▲     入院日期:     93/2/10     下午     04:24:10       診     斷:     1     151     胃惡性腫瘤	- 選取患者(Q) 離開(E)
		確定(エ)
評估資料1 評估資料2 配方及添加物 歷9	史資料 FOCUS値	
身 高: 161 公分 理想間	豊重: 57.07 公斤	
	豊重: 55 公斤	
CNSS Dietition: 31464 高振渾		
由 CNSS 營養師填寫:		
Triceps Skinfold 三頭肌皮下脂肪厚度 (T	rsf) 19 mm	
Midarm Circumference 上臂圈 (MAC)	26 cm	
肌肉臂圈 (MAMC)	20 cm	
Total Lymphocytes Count 淋巴球總數 (TL	$\mathcal{L}$ ) 1534 /mm <sup>3</sup>	
Creatinine Height Index (CHI)	0 %	
Muscle Wasting 肌肉耗損 NONE	<b>•</b>	
Fat Tissue Wasting 皮下脂肪耗損 NONE	▼	
Edema 水腫 NONE	▼	
Weight Change 24.6 % for 2	C month C year	
Dietary History Caloric Intake 500	kcal/day for 2 🛛 🔿 week 🔿	month

🏄 開始 📔 📀 💽 🥌 » 🛛 🖸 行事... 🖾 Tpn... 🧤 Ultra... 🦓 C++... 🔽 2 O... 🗸 🎄 彰基... 🚺 Nutiass 🗍 🖮 🛱 « 🔧 🐢 下午 05:30

病 歴 號: <sup>3845243</sup> 姓名:
確定(Y)
評估資料1 評估資料2 配方及添加物   歷史資料   FOCUS値
Consultant's Notes:
Daily Nutrient Requirement:
BEE 基礎能量需要量 1142 kcal 實際體重 ▼ 55 m
(Stress factor 壓力因子 1.5 Activity factor 活動因子 1.2 )
Total Calorie Requirement 總熱量需要量 2056 kcal
Protein Requirement 蛋白質需要量
N: non-Protein Calorie 氮:非氮熱量: 1:124
。
patient has severe weight loss for >1.5 months and poor oral intake, we use TPN for preoperative nutrition support.

² 開始 🛛 📀 💽 🥌 » 🛛 🖸 收... 🖾 Tp... 🮯 Ult... 👹 C+... 🔽 2 O 🗸 🎄 彰... 🚺 Nut... 🗐 文... 🗍 🖮 🛱 « 🔧 🐢 下午 05:32

×

林佳靑[TPN12]	TPN	12 TPN營養評估功能_正式	式	本院-KDK04[1	92.168.181.26]
病 歷 號:26155365	姓名:	──────────────	年齡:56 成人	、 	離開(E)
住院帳號:700332431	床號: K 613 C	入院日期:2005/4	/14 13:12:10	━ 選収応伯(型)	
主治醫師:37599 陳自調	<u></u>	診 斷:1 15	3.0 結腸右曲惡性	-	



常用功能

索肌

 $\langle |$ 


個案管理

 TPN系統

居家照護

掛號系統 >


05/12 19:30:14



#### **Solutions and Additives**

- 🖌 🛛 Lipids
  - a. Used as a calorie source and to prevent fatty acid deficiency (4-10% of the total daily calories as linoleic acid is necessary to provide essential fatty acid supplementation).
  - Fat emulsions are available as a 10%LCT product which is 1.1 Kcal/cc and a 20% product which is 2.0 Kcal/cc (MCT/LCT=50:50).
  - c. Fat emulsions should not more than 60% of the total calorie input of the patient (even in the most immune compromised patients).

林佳靑[TPN12]	TPN	12 TPN營養評估功能_正:	式	本院-KDK04[1	92.168.181.26]
病 歴 號:26155365	姓名: 鄭明火		年齡:56 成人	- 選取患者(Q)	<u>雜問/₽\</u>
住院帳號:700332431	床號: K 613 C	入院日期:2005/4	1/14 13:12:10	进权芯相(및)	
主治醫師:37599 陳自詞	<u></u>	診 斷:1 15	3.0 結腸右曲惡性 🔻	1	



常用功能

索

<

個案管理

 TPN系統

居家照護

掛號系統 >

05/12 19:32:49

林佳靑[TPN12]	TPN	12 TPN營養評估功能_正:	式	本院-KDK04[192.168.181.26]
病 歴 號:26155365	姓名: 鄭明火		年齡:56 成/	人 選取患者(Q) 離開(E)
住院帳號:700332431	床號: K 613 C	入院日期:2005/4	4/14 13:12:10	
主治醫師:37599 陳自詞	<u>,</u>	診 斷:1 15	3.0 結腸右曲惡性	



常用功能

索

< 個案管理


 TPN系統

居家照護

掛號系統 >

05/12 19:35:24

林佳靑[TPN12]	TPN	12 TPN營養評估功能_正:	式	本院-KDK04[192.168.181.26]
病 歴 號:26155365	姓名: 鄭明火		年齡:56 成/	人 選取患者(Q) 離開(E)
住院帳號:700332431	床號: K 613 C	入院日期:2005/4	4/14 13:12:10	
主治醫師:37599 陳自詞	<u>,</u>	診 斷:1 15	3.0 結腸右曲惡性	



常用功能

索

< 個案管理

TPN系統

居家照護

掛號系統 >

05/12 19:34:05








×



🖮 🛱 < <u>条</u> 🐢 下午 05:32



🕑 💽 🥶 » 🛛 🖸 收... 🖾 Tp... 🥢 Ult... 👹 C+... 🍰 2 O - 🎪 彰... 🚺 Nut... 🗐 文...

🏉 開始 📋

### **Clinical application of parenteral nutrition**



高振渾[TPN]	2] TPN12 TPN營養評估功能_正式 本院-STEVENKAO[192.	168.199.205]
病歷號	・2045242 ある・林光市 あいいし アホ・ワイーン・	
// 在 》 住院帳號		開(E)
主治醫師	一配方及計算公式	
土伯茜則	● 以糖為基準 ● 以蛋白質為基準 ● 強制 ● 取消 確定 取消	
	X = 總熱量 T = 配方數量 Y = 蛋白質 P = 外加量 Z = 患者所需葡萄糖克數	定(1)
評估資料	公式一   公式二   OTHERS	
配方	(X(脂肪瓶數*_cc數_*2_) -(_Y*4_)) / 3.4 = Z	計算
· · ·	( <b>2081</b> - ( <b>1</b> * <b>250</b> *2) -( <b>79</b> * 4)) / 3.4 = <b>372</b>	長疽 ▲
● 一般	Y / Amino Acid % = $T(ml)$	20
配方別:	79 / $3.846$ % = $2054$	40
TCR(總索	Z - T * Dextrose% = G(g)	14
AMINOAC	372 - 2054 * 18.1 % = 0	0
Dextros	G / %G/W = P(ml)	6
糖:	0 / 50 % = 0	200
脂肪:	實際供應熱量 <b>79 *4+ 372 *</b> 3.4+ <mark>250 *2= 2081 kcal</mark>	
蛋白質:		
醫師輸2	蛋白質比 79 *4/ 2081 *100= 15.18 %	
INTRAFA	糖比 372 *3.4/ 2081 *100= 60.77 %	
PROTEIN	脂肪比 250 *2/ 2081 *100= 24.02 %	
建議糖常	Dextrose 372 / 55 /1440*1000= 4.69 mg/kg/min	
建議氮與	N:NPC 1: 140	
	每小時cc數 <mark>2058</mark> / 24 = <mark>86 </mark> cc/hr	-
🏄開始 🛛 🤇	🔉 💽 🥌 » 🛛 📴 收 🖾 Tp 🞯 Ult 👹 C+ 🛃 2 O 🗸 🎪 彰 🚺 Nut 🗐 文 🗍 🖮 🛱 « 🤧 👧	下午 05:33

高振渾[TPN12]	TPN	112 TPN營養評估功能_正式	式	本院-STEVENKA0[192.168.199.205]
	姓名: 床號: K 651 A	性別:M 入院日期:93/2/1	年齡: <mark>71</mark> 成人 0下午 04:24:10	
主治醫師:21591 張宏基		診 斷:1 15	1 胃惡性腫瘤	
				確定(1)
評估資料1  評估資料2  配方	牙及添加物 歷史資料	역  FOCUS値		
複製删除停	用 原因: O Enter	ral nutrition 🗨	觀察中 C MBD	⊙ AAD ⊙ HL ⊙ 其他
序 類別  結案原因		實際體重 理想體重		〖下脂肪厚度 上臂圍肉臂▲
	02/11 15:26 161	55 57.07	55	19 26
	02/11 15:26 161	55 57.07	55	19 26
▶ 1 一般	02/11 15:24 161	55 57.07	55	19 26
				▼ ▶
項目 建議項目	建議量 類別 📃	營養師建議		
▶ 1 TPNF	2054 F			
2 G/W-TPN	0 G	patient has se	evere weight loss ike, we use TPN f	for >1.5 months and
3 LIPOFUNDIN MCT/LC		nutrition supp		
4 AMINOSYN-TPN INJ	0 P			
5 MULTIVITA-TPN	2 A			
6 TRACE ELEMENT-TPN	2 A			

🦺開始 🛛 📀 💿 🥔 » 🛛 🖸 收... 🖾 Tp... 🥡 Ult... 💏 C+... 🛃 2 O 🗸 🎪 彰... 🚺 Nut... 🗐 文... 🗍 🖮 🛱 « 🦜 🕸 下午 05:33

#### **Role of Nutrition Support Team Members**

#### 🎸 Pharmacist

- 1. Assess the stability and the compatibility of the parenteral nutrition solution.
- Assist the physician in initiating, maintaining, and monitoring the therapy's affect on the patient's metabolic condition.
- 3. Provide educational programs on select parenteral nutrition topics.
- Assist in the coordination and arrangement of home therapy prescriptions.

財團法人彰化基督教醫院 臨床營養醫療支援小組	病歷號碼: 16006581 性別: 女
會診單(成人)	姓名:
CONSULTATION SHEET (ADULT)	床 號: K-SIC-11 年齡: 64
病情摘要:	
Request臨床營養醫療支援小組Consultation	
Diagnosis:2 518.81 呼吸衰竭	3 686 皮膚及皮下組織之其他局部感染
6 401.9 自發性高血壓,未明示為惡性或良性	8 599.0 泌尿道感染,未明示位置者
10 996.62 其他血管裝置物、種植及移植物所	
13 558.9 其他及未明示之非傳染性胃腸炎及力	大腸炎14 709.2 疤痕病態及反膚纖維化
Clinical Summary:	and a second stands in the second sec
	ocutaneous fistula, ischemia bowel post op,
DM with medical control. This time she admitted t to a lot of discharge from endtrocutaneous fistu	
for further nutrition suport due to NPO, thanks	
Nutrition Assessment Required Data:	a 10111
Height 146(Cm)	Dept. 201 一般外科 Referred by Dr. 楊力
Actual wt. 48(Kg) IBW 46.94(Kg) or AdjBW 48	
回覆內容:	
Nutrition Assessment Parameter:	
Total lymphocytes count(TLC) 330 (/mm3)	
Creatinine height index (CHI) 53 (%) Muscle wasting mild-moderate	
Fat tissue wasting mild-moderate	
Edema mild-moderate	
Dietary history caloric intake 1500 (kcal/	(day) for 1 month
Consultant's Notes:	
Daily Nutrient Requirement:	
BEE 1078 kcal (Stress factor 1.5 Acti	ivity factor 1.2 )
Total calorie requirement 1860 (kcal)	
Protein requirement 56 (g)	
N: non-protein calorie: 1:183	
Nutrition Support Suggestion:	
	ng, now she can't use enteral feeding, so we
use TPN for nutrition support.	CNSS Dietitian: 廖婉如
	Date: 2004/2/13 下午 04:06:48
Nutritional Order:	Date. 200472713 1 + 04.00.46
Consultation indicator:	
<ul> <li>Moderate stress when enteral diet is not expect</li> </ul>	ted to resume in 7 days
<ul> <li>Enterocutanous fistula /Enteric anastomotic les</li> </ul>	
Method:	
<ul> <li>Parenteral Nutrition</li> </ul>	主治醫師王淑惠
- Falchtelal Nutlition	
• Central	
	CNSS Physician: Rate:2004/2/13 下午 04:06:48

#### **General recommendations for TPN monitoring**



### **Role of Nutrition Support Team Members**

#### 🕹 Nurs</mark>e

- 1. Be a resource person for <u>patients</u>, <u>staff</u> and <u>local health</u> <u>care providers</u> regarding parenteral nutrition therapy and central venous catheters.
- Monitor quality care for parenteral nutrition therapy and central venous catheters.
- 3. Participate in the discharge planning and patient education of home parenteral nutrition therapy patients.
- Follow-up with home parenteral nutrition therapy patients after discharge from the hospital.

#### **Role of Nutrition Support Team Members**

#### Dietitian


- Assess the nutritional status of the patient and determine nutritional needs.
- Develop and implement a plan of nutritional care based on assessment of needs.
- 3. Monitor and evaluate nutritional status on an ongoing basis and recommend changes as needed.
- Educate patients, physicians, and other health professionals on types and methods of nutritional support for hospital and home use.

#### 🆺 TPN營養評估功能 性別:F 病 歴 號:6348809 年齡:66 成人 姓名: 選取患者(Q) 離開(E) 入院日期:2002/7/12 上午 08:03:09 住院帳號:700070854 床號: K 701 主治醫師:61303 于振東 斷:[ 診 Ŧ 確定(Y) ₽₽₽₽₽₽₽₽₽ 評估資料1 離開 存檔 序値 FOCUS值 ▶ 1 YY 説明 確定 放棄 CH 值 FOCUS描述 説明 形成時間 ۰ ΥY TTT GG GGGGERRR ₹ İ •

//.


## 彰基執行TPN現況分享


民國八十九年醫學中心成立後,重症急患人數增加,因而會診靜脈營養支持小組人數也陸續增加。




民國92年2月份開始起用電腦照會與回覆系統,總 接案數416人/年;共計7251人日數/年

平均每日案數為27.5人日數/天









#### **Total Parenteral Nutrition indicator**

- 1. Enterocutanous fistula /Enteric anastomotic leakage
- 2. Hyperemesis gravidarum
- 3. Inability to absorb nutrients via the gastrointestinal tract
- 4. Inflammatory bowel disease when bowel rest for 2-4 weeks is indicated
- 5. Intractable diarrhea
- 6. Major surgery when adequate enteral intake is not expected to resume within 7-10 days
- 7. Massive bowel resection(SBS)
- 8. Moderate stress when enteral diet is not expected to resume in 7 days
- 9. Moderate to severe acute pancreatitis
- 10. Patients undergoing high-dose antineoplatic therapy(Chemotherapy/Radiotherapy)
- 11. Severe catabolism with or without malnutrition when the gastrointestinal tract is nonfunctional for 5-7 days
- 12. Severe malnutrition with a temporary(5-7 days) nonfunctional tract





# THANKS FOR YOUR ATTENTION